64 related articles for article (PubMed ID: 18589207)
1. Exosomal microRNAs step into the biomarker arena.
Shih KK; Levine DA
Gynecol Oncol; 2008 Jul; 110(1):1-2. PubMed ID: 18589207
[No Abstract] [Full Text] [Related]
2. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform.
Resnick KE; Alder H; Hagan JP; Richardson DL; Croce CM; Cohn DE
Gynecol Oncol; 2009 Jan; 112(1):55-9. PubMed ID: 18954897
[TBL] [Abstract][Full Text] [Related]
3. Systemic microRNAs: novel biomarkers for colorectal and other cancers?
Heneghan HM; Miller N; Kerin MJ
Gut; 2010 Jul; 59(7):1002-4; author reply 1004. PubMed ID: 20581247
[No Abstract] [Full Text] [Related]
4. Plasma microRNAs: a potential biomarker for colorectal cancer?
Schetter AJ; Harris CC
Gut; 2009 Oct; 58(10):1318-9. PubMed ID: 19749133
[No Abstract] [Full Text] [Related]
5. A truth serum for cancer--microRNAs have major potential as cancer biomarkers.
Chin LJ; Slack FJ
Cell Res; 2008 Oct; 18(10):983-4. PubMed ID: 18833286
[No Abstract] [Full Text] [Related]
6. Transthyretin, a biomarker for nutritional status and ovarian cancer.
Schweigert FJ; Sehouli J
Cancer Res; 2005 Feb; 65(3):1114; author reply 1114. PubMed ID: 15705915
[No Abstract] [Full Text] [Related]
7. [Biological factors with prognostic significance in ovarian cancer].
Ferrandina G; Legge F; Fagotti A; Fanfani F; Mancuso S; Scambia G
Minerva Ginecol; 2001 Feb; 53(1 Suppl 1):40-5. PubMed ID: 11526718
[No Abstract] [Full Text] [Related]
8. Forensic bioinformatician aims to solve mysteries of biomarker studies.
Savage L
J Natl Cancer Inst; 2008 Jul; 100(14):983-7. PubMed ID: 18612123
[No Abstract] [Full Text] [Related]
9. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
[TBL] [Abstract][Full Text] [Related]
10. Genetic analysis of cancer-implicated MicroRNA in ovarian cancer.
Bearfoot JL; Choong DY; Gorringe KL; Campbell IG
Clin Cancer Res; 2008 Nov; 14(22):7246-50. PubMed ID: 19010840
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic markers for ovarian cancer screening: not ready for routine clinical use.
Coates RJ; Kolor K; Stewart SL; Richardson LC
Clin Cancer Res; 2008 Nov; 14(22):7575-6; author reply 7577-9. PubMed ID: 18948387
[No Abstract] [Full Text] [Related]
12. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer.
Hu X; Macdonald DM; Huettner PC; Feng Z; El Naqa IM; Schwarz JK; Mutch DG; Grigsby PW; Powell SN; Wang X
Gynecol Oncol; 2009 Sep; 114(3):457-64. PubMed ID: 19501389
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1.
Guo LM; Pu Y; Han Z; Liu T; Li YX; Liu M; Li X; Tang H
FEBS J; 2009 Oct; 276(19):5537-46. PubMed ID: 19702828
[TBL] [Abstract][Full Text] [Related]
14. A step forward in miRNA diagnostics: new and improved protocols for miRNA measurement.
Miller S
Bioanalysis; 2012 Jan; 4(2):121. PubMed ID: 22250794
[No Abstract] [Full Text] [Related]
15. Biomarkers and clinical trial design.
Farley J; Bast RC; Birrer MJ
Gynecol Oncol; 2006 Nov; 103(2 Suppl 1):S3-5. PubMed ID: 17027069
[No Abstract] [Full Text] [Related]
16. Role of microRNAs in drug-resistant ovarian cancer cells.
Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
[TBL] [Abstract][Full Text] [Related]
17. Gene-expression profiling in epithelial ovarian cancer.
Konstantinopoulos PA; Spentzos D; Cannistra SA
Nat Clin Pract Oncol; 2008 Oct; 5(10):577-87. PubMed ID: 18648354
[TBL] [Abstract][Full Text] [Related]
18. Carcinosarcoma of the ovary a review.
Cantrell LA; Van Le L
Obstet Gynecol Surv; 2009 Oct; 64(10):673-80; quiz 697. PubMed ID: 19772676
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs in clinical oncology: at the crossroads between promises and problems.
Metias SM; Lianidou E; Yousef GM
J Clin Pathol; 2009 Sep; 62(9):771-6. PubMed ID: 19734473
[TBL] [Abstract][Full Text] [Related]
20. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
